ClinicalTrials.gg
RecruitingNCT06775860Updated Sep 8, 2025

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of ICP-332 Tablets and ICP-332 Placebo Tablets in Atopic Dermatitis, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 62 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
552
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
21st of 190
552 · median 164
Started
2024
with 36 others
Phase 3
60 of 206
21 open now
Primary completion
2026-11
later than 31 of 81 live
Registered
134th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 21st largest by planned enrollment of the 190 interventional ones that give a count, is one of 37 that started in 2024, is one of 60 in phase 3, reaches primary completion later than 31 of the 81 other live ones, and was the 134th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 18 and 75 years of age.
  2. Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for at least 1 year
  3. Documented recent history of inadequate response to TCS or TCI, or for whom topical treatments are otherwise medically inadvisable.
  4. Subjects must meet the following criteria for disease activity:

    • Eczema Area and Severity Index (EASI) score ≥ 16 ;
    • (Body Surface Area )BSA affected by AD ≥ 10% ;
    • (validated Investigator's Global Assessment-AD)vIGA-AD score ≥3 ;
    • Baseline weekly average of daily Worst Pruritus NRS ≥ 4.
  5. Women of (WOCBP) and Men must agree

5. Women of childbearing potential (WOCBP) and Men must agree to . 6. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Lack of response or inadequate response to prior treatment with any JAK inhibitor for AD.
  2. Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions.
  3. Pregnant or breastfeeding females.
  4. History of any clinically major diseases, with the exception of atopic dermatitis.
  5. Consideration by the Investigator, for any reason, that the subject is an unsuitable candidate to receive ICP-332 or participate in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
552 participants (estimated)

Study arms

  • Experimental
    ICP-332

    Drug: ICP-332 Tablets

  • Placebo comparator
    Placebo

    Drug: ICP-332 Placebo Tablets

Interventions

  • ICP-332 will be administered as tablet

  • DrugICP-332 Placebo Tablets

    ICP-332 Placebo will be administered as tablet

06

What researchers measure

Primary outcomes

  1. Proportion of subjects achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75) from Baseline

    Time frame: 16 weeks

  2. Proportion of subjects achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 with at least two grades of reduction from Baseline

    Time frame: 16 weeks

07

Study locations

62 of 62 sites recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
    Recruiting
    • Zaixing Wang · Contact
  • The Second Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241000, China
    Recruiting
    • Ruzhi Zhang · Contact
  • Capital Medical University Affiliated Beijing Chaoyang Hospital
    Beijing, Beijing Municipality 100020, China
    Recruiting
    • Fang Liu · Contact
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
    Recruiting
    • Hang Li · Contact
  • Capital Medical University Affiliated Beijing Friendship Hospital
    Beijing, Beijing Municipality 100050, China
    Recruiting
    • Linfeng Li · Contact
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
    Recruiting
    • Chunlei Zhang · Contact
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality 100730, China
    Recruiting
    • Aihua Wei · Contact
  • Beijing Tsinghua Changgung Hospital
    Beijing, Beijing Municipality 102218, China
    Recruiting
    • Yi Zhao · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
    Recruiting
    • Aijun Chen · Contact
  • Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Chongqing Municipality 400021, China
    Recruiting
    • Qingchun Diao · Contact
  • The Affiliated Union Hospital of Fujian Medical University
    Fuzhou, Fujian 350001, China
    Recruiting
    • Huichun Su · Contact
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
    Recruiting
    • Chao Ji · Contact
  • The Second Affiliated Hospital of Xiamen Medical College
    Xiamen, Fujian 361021, China
    Recruiting
    • Mingkai Ji · Contact
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
    Recruiting
    • Yunsheng Liang · Contact
  • Zhongshan University Sun Yat-sen Memorial Hospital
    Guangzhou, Guangdong 510120, China
    Recruiting
    • Liangchun Wang · Contact
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong 510515, China
    Recruiting
    • Yue Zheng · Contact
  • Yuebei People's Hospital
    Shaoguan, Guangdong 512026, China
    Recruiting
    • Weiquan Li · Contact
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518035, China
    Recruiting
    • Wenzhong Wu · Contact
  • Liuzhou People's Hospital
    Liuzhou, Guangxi 545006, China
    Recruiting
    • Min Xiao · Contact
  • Affiliated Hospital of Chengde Medical University
    Chengde, Hebei 067000, China
    Recruiting
    • Xinsuo Duan · Contact
  • Affiliated Hospital of Hebei University of Engineering
    Handan, Hebei 056002, China
    Recruiting
    • Guoying Miao · Contact
  • Second Affiliated Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Recruiting
    • Yanling Li · Contact
  • The Second Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471000, China
    Recruiting
    • Lin Chen · Contact
  • Sanmenxia Central Hospital
    Sanmenxia, Henan 472000, China
    Recruiting
    • Danhong Jiao · Contact
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
    Recruiting
    • Jianguo Li · Contact
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
    Recruiting
    • Yi Sun · Contact
  • Wuhan Central Hospital
    Wuhan, Hubei 430014, China
    Recruiting
    • Ying Gao · Contact
  • Wuhan Hospital of Traditional Chinese and Western Medicine (Wuhan No.1 Hospital)
    Wuhan, Hubei 430022, China
    Recruiting
    • Liuqing Chen · Contact
  • Central South University Xiangya Hospital
    Changsha, Hunan 410008, China
    Recruiting
    • Juan Su · Contact
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
    Recruiting
    • Rong Xiao · Contact
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 010050, China
    Recruiting
    • Xinxiang Lv · Contact
  • Changzhou First People's Hospital
    Changzhou, Jiangsu 213003, China
    Recruiting
    • Yanxia Yuan · Contact
  • Sir Run Run Hospital, Nanjing Medical University
    Nanjing, Jiangsu 211166, China
    Recruiting
    • Bin Chen · Contact
  • Yancheng First People's Hospital
    Yancheng, Jiangsu 224001, China
    Recruiting
    • Pingping Qin · Contact
  • The First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi 341000, China
    Recruiting
    • Jingfa Lu · Contact
  • Affiliated Hospital of Jiujiang University
    Jiujiang, Jiangxi 332000, China
    Recruiting
    • Qiuhe Song · Contact
  • Jiangxi Provincial Dermatology Hospital
    Nanchang, Jiangxi 330001, China
    Recruiting
    • Guohong Hu · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Xianwei Cao · Contact
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
    Recruiting
    • Shanshan Li · Contact
  • Shenyang Hospital of Integrated Traditional Chinese and Western Medicine (Shenyang Seventh People's Hospital)
    Shenyang, Liaoning 110001, China
    Recruiting
    • Yan Liu · Contact
  • Zhongyi Northeast International Hospital Co., Ltd.
    Shenyang, Liaoning 110179, China
    Recruiting
    • Shifa Zhang · Contact
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
    Recruiting
    • Yan Zheng · Contact
  • Shaanxi Provincial People's Hospital
    Xi'an, Shaanxi 710068, China
    Recruiting
    • Li Yang · Contact
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Recruiting
    • Ying Li · Contact
  • Shandong Provincial Dermatosis Hospital
    Jinan, Shandong 250022, China
    Recruiting
    • Furen Zhang · Contact
  • Jining First People's Hospital
    Jining, Shandong 272011, China
    Recruiting
    • Dongmei Shi · Contact
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266003, China
    Recruiting
    • Guanzhi Chen · Contact
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai Municipality 200072, China
    Recruiting
    • Jun Gu · Contact
  • Shanghai First People's Hospital
    Shanghai, Shanghai Municipality 200080, China
    Recruiting
    • Zhouwei Wu · Contact
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality 200443, China
    Recruiting
    • Yangfeng Ding · Contact
  • Yuncheng Central Hospital
    Yuncheng, Shanxi 440000, China
    Recruiting
    • Juanli Fan · Contact
  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610017, China
    Recruiting
    • Yanyan Feng · Contact
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
    Recruiting
    • Lixia Zhang · Contact
  • General Hospital of Tianjin Medical University
    Tianjin, Tianjin Municipality 300052, China
    Recruiting
    • Huiping Wang · Contact
  • Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine
    Tianjin, Tianjin Municipality 300120, China
    Recruiting
    • Litao Zhang · Contact
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
    Recruiting
    • Weijia Zhao · Contact
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang 310006, China
    Recruiting
    • Liming Wu · Contact
  • The Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Recruiting
    • Xiaoyong Man · Contact
  • The Third People's Hospital of Hangzhou
    Hangzhou, Zhejiang 310009, China
    Recruiting
    • Aie Xu · Contact
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang 315010, China
    Recruiting
    • Bingjiang Lin · Contact
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
    Recruiting
    • Zhiming Li · Contact
  • The Fourth Affiliated Hospital, Zhejiang University School of Medicine
    Yiwu, Zhejiang 322000, China
    Recruiting
    • Lunfei Liu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 24 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2024
First posted
Jan 15, 2025
StartActual
Nov 14, 2024
Primary completionEst.
Nov 25, 2026
CompletionEst.
Dec 25, 2026
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06775860
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Nov 14, 2024
Primary completion
Nov 25, 2026 (estimated)
Completion
Dec 25, 2026 (estimated)
Last update
Sep 8, 2025

Study contacts

Pengcheng Lei
Contact
pengcheng.lei@innocarepharma.com
+86 18501252185

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-332

Start the discussion